EUROCHIP-3EUROCHIP-3: : WP-4 PublicationsWP-4 Publications

http://www.tumori.net/eurochip

Paolo Baili Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy

ALREADY PUBLISHED

• Monograph on EUROCHIP-2 activities on cervical cancer screening

• Various articles on cervical epidemiological data in Europe and in the world by marc Arbyn

• EUROCHIP-3 work in Estonia

• Cancer World article

FUTURE

• Articles on the WP-4 studies on cervical cancer screening in Lithuania, Latvia, Romania and Bulgaria WP4 (TBD)

EUROCHIP-3 PUBLICATIONS

EUROCHIP-3 WP-5 & 6EUROCHIP-3 WP-5 & 6: : Publications Publications

http://www.tumori.net/eurochip

Paolo Baili Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy

EUROCHIP PAST PUBLICATIONS

• Chapter on “Cancer Information” for Slovenian Presidency cancer book

• Chapter on cancer for the EUGLOREH (European Global Report on Health)

• Chapter on cancer for the European Commission Report on Major and Chronic Diseases

• Cancer control book chapter on cancer indicators

• Article on the availability of cancer registry indicators as studied in EUROCHIP-3 WP-5

• Article ready at 80%

• Title: Cancer registry indicators for cancer care in Europe

• First author: Sabine Siesling

• Author authors: A.Kwast, A.Gavin, P.Baili, R.Otter &

• EUROCHIP WP-5 Working group: list of cancer registries participating in the survey

FUTURE EUROCHIP-3 WP-5 PUBLICATIONS

• 1 article in Cancer World already published

• Article on cancer rehabilitation indicators and literature research on methods and sources as studied in EUROCHIP-3 WP-6 (ready at 80%) – First Author: P. Baili

• Article on cancer rehabilitation status across Europe as studied in EUROCHIP-3 WP-6 (ready at 80%) – First Author: E. Van Hoof

• Both articles have EUROCHIP WP-6 Working group with the list of experts involved in the WP-6 surveys and discussions

FUTURE EUROCHIP-3 PUBLICATIONS

Polish contribution to WP-6

Country specific papers:

• Cancer patients rehabilitation in Poland. State of art by Malgorzata Gajewska, Maria Piotrowicz, Dorota Cianciara, Anita Gebska-Kuczerowska, Ewa Urban, Rafal Halik, Nina Bylicka-Karczewska, Magdalena Bielska-Lasota

• Selected aspects of palliative care in Poland by Justyna Car, Jerzy Jarosz, Anna Debska, Magdalena Bielska-Lasota

EUROCHIP-3EUROCHIP-3: : WP-4 ConclusionsWP-4 Conclusions

http://www.tumori.net/eurochip

Paolo Baili Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy

WP-4 CONCLUSIONSCervical cancer screening adherence in Eastern

EU MS

• Several European organizations and networks lead projects in this area

• EUROCHIP focused on specific barriers characterizing the implementation of CC programs in Eastern Europe

• Together with other networks, EUROCHIP provided the local experts with a European umbrella for the promotion of effective screening

• We do think to have helped these countries to improve (or at least to identify how to improve) the status of cervical cancer screening

EUROCHIP WP-5 & 6EUROCHIP WP-5 & 6: : Conclusions Conclusions

http://www.tumori.net/eurochip

Paolo Baili Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy

WP-5 CONCLUSIONSCancer registry indicator availability and

promotion• EUROCHIP is not a project on data collection but

a project on the promotion of data collection and their use for cancer control

• Cancer registries should be recognized to cover a central role in cancer control

• Collection of health indicators in a comparable way across the EU enables health planners locally to identify the existing major inequalities and act on them

• European projects and networks allow to collect indicators by cancer registries with standardized approaches and protocols

WP-6 CONCLUSIONSCancer rehabilitation indicators

• Relatively new area in the population-based approach

• Most of the suggested indicators require validation via research studies and to assess ways to collect them

• This is should be regarded as an important area for future work

• The epidemic of prevalent cases require more and more attention on the rehabilitation field

• We hope EUROCHIP, as other networks, have helped to increase the attention on this field

EUROCHIP-3EUROCHIP-3: : WP-7 ConclusionsWP-7 Conclusions

http://www.tumori.net/eurochip

Paolo Baili Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy

THE EUROCHIP WP7 EXPERIENCE - 1 HE EUROCHIP WP7 EXPERIENCE - 1

InequalityInequality. WP7 worked on the issue of cancer cost . WP7 worked on the issue of cancer cost having in mind the paradox that links having in mind the paradox that links

the economy of our societies the economy of our societies to cancer outcome:to cancer outcome:

cancer health disparities are expected cancer health disparities are expected to last in the future as the differences to last in the future as the differences

in economies. in economies. if expenses for cancer are if expenses for cancer are investments investments

not costsnot costs

our societies may decide to give to EU citizens a chance our societies may decide to give to EU citizens a chance to escape from the paradoxto escape from the paradox

THE ROLE OF PATIENTS IS FUNDAMENTAL

THE EUROCHIP WP7 EXPERIENCE - 2HE EUROCHIP WP7 EXPERIENCE - 2

EU scale.EU scale. WP7 worked on the issue of cancer cost WP7 worked on the issue of cancer costtaking advantage of the EU scale:taking advantage of the EU scale:

each Member State each Member State may understand may understand

its own health system performance its own health system performance by improving information system by improving information system

and check health practice and check health practice by collaboration between countries. by collaboration between countries.

if cost is one of the major determinants if cost is one of the major determinants of the outcome (drugs, diagnostic procedures, organisation) of the outcome (drugs, diagnostic procedures, organisation)

a a scale economyscale economy is the key: is the key: EU is becoming the solutionEU is becoming the solution

THE ROLE OF EU IS FUNDAMENTAL

THE EUROCHIP WP7 EXPERIENCE - 3HE EUROCHIP WP7 EXPERIENCE - 3

HTA STUDIESHTA STUDIES. WP7 worked on the issue of cancer cost. WP7 worked on the issue of cancer costby proposing to look at major components by proposing to look at major components

of cancer management in terms of cost:of cancer management in terms of cost:Cancer guidelines may be studied in terms of HTA. Cancer guidelines may be studied in terms of HTA.

If cancer cost is not considered a problem in EUIf cancer cost is not considered a problem in EUHTA studies are not adequately supported: HTA studies are not adequately supported:

cost/effectiveness studies are the keycost/effectiveness studies are the key for trying to overcome GDP limitations for trying to overcome GDP limitations

THE ROLE OF HTA STUDIES IS FUNDAMENTAL

THE EUROCHIP WP7 EXPERIENCE - 4HE EUROCHIP WP7 EXPERIENCE - 4KEY POINTS

minimum requirement sets of cancer toolsmultidisciplinary activity

identify reasons for cost increase

POLITICAL ACTION

advancement in cancer research: studies that consider the cost issue should be supported

A EU CANCER CONTROL COMMUNITY IS FUNDAMENTALNOTHING ABOUT THEM WITHOUT THEM

EUROCHIPEUROCHIP: : Near FutureNear Future

http://www.tumori.net/eurochip

EUROCHIPEUROCHIP: : European Cancer European Cancer Health Indicator ProjectsHealth Indicator Projects

http://www.tumori.net/eurochip

EPAACEPAAC: The European Partnership : The European Partnership for Action Against Cancerfor Action Against Cancerhttp://www.epaac.eu/

WP1: Coordination & Management

WP2: Dissemination, Virtual partnership

WP4: Secretariat, Open Forum

WP3: Evaluation

WP5: Health Promotion and

Prevention

WP6: Screening and early diagnosis

WP8: Research

WP7: Healthcare

WP9: Information

& data

WP10: Cancer plans

EPAAC WP-9 aimsEPAAC WP-9 aims

LINK WITH EUROCHIP-3 WP-5 • Evaluate a standard protocol for collection of

data on stage, clinical standards, treatments, etc to be used by EU cancer registries in comparable studies

LINK WITH EUROCHIP-3 WP-6• Discuss a standard protocol for collection of

data on survivorship indicators to be used by EU cancer registries in comparable studies

• AIM: To enlarge WP-6 discussion to the world of cancer registries

EUROCHIPEUROCHIP: : Long term futureLong term future

http://www.tumori.net/eurochip

STATUS AND SOME IDEASSTATUS AND SOME IDEAS

• FUTURE: DG-SANCO call for proposal for 2013

• MAIN RESEARCH INTEREST: cancer survivors needs

• Proposals:• Pilot studies on cancer survivorship indicators (i.e.

qualified prevalence)• Cured prevalence from EUROCARE-5• Research studies on QoL indicators